There is strong evidence from the clinical trials that SGLT2 inhibitors should be prioritized in patients with T2DM and CKD with a presenting GFR of 30-40mL/min/1.73m2. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.